Skip to content

The French EsoGastricTumours Data Base

National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02526095
Acronym
FREGAT
Enrollment
15000
Registered
2015-08-18
Start date
2014-06-01
Completion date
2027-05-01
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Disease

Keywords

Esophagus, Surgery

Brief summary

This retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery.

Interventions

None listed

Sponsors

University Hospital, Lille
Lead SponsorOTHER
French Eso-Gastric Tumors Working Group
CollaboratorOTHER
National Cancer Institute, France
CollaboratorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Patient with * esophageal cancer, gastric or gastroesophageal junction diagnosed biopsy , regardless of the subtype of cancer, tumor stage or treatment envisaged. * Naive treatment for this cancer, * Naive treatment for this cancer , failing that received neoadjuvant treatment , * Male or female ≥ 18 years. * social protection scheme . * sign a free and informed consent for blood sampling , the different questionnaires and the collection of patient information.

Exclusion criteria

Male or female aged ( e) under 18 years. * Private person of liberty or under supervision (including guardianship ) . * People who do not speak French. * Major Nobody unable to consent . * Patient FREGAT already included in the base. * Patient Refusal .

Design outcomes

Primary

MeasureTime frame
DIsease free survival5 year disease free survival

Secondary

MeasureTime frame
overall survival5 year overall survival
recurrence rate5 year recurrence rate
Total number of patients with complicationsfrom the time between inclusion and occurrence of the event, for the duration of 3 years
Total number of complicationsfrom the time between inclusion and occurrence of the event, for the duration of 3 years
Deathfrom the time between inclusion and occurrence of the event, for the duration of 3 years

Countries

France

Contacts

CONTACTGuillaume Piessen, MD, PhD
guillaume.piessen@chru-lille.fr+3320444407
STUDY_DIRECTORGuillaume Piessen, MD, PhD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026